Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

The aim of this study was to explore the efficacy and safety of obinutuzumab (G)- versus rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal zone lymphoma (MZL) in the phase III GALLIUM trial (NCT01332968). Patients had stage III/IV (or stage II with bulky disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Herold, Michael, Hoster, Eva, Janssens, Ann, McCarthy, Helen, Tedeschi, Alessandra, Pocock, Chris, Rosta, Andras, Trněný, Marek, Nielsen, Tina G., Knapp, Andrea, Hiddemann, Wolfgang, Marcus, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878871/
https://www.ncbi.nlm.nih.gov/pubmed/35233508
http://dx.doi.org/10.1097/HS9.0000000000000699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878871/
https://www.ncbi.nlm.nih.gov/pubmed/35233508
http://dx.doi.org/10.1097/HS9.0000000000000699

Ejemplares similares